Cartalax vs bpc-157
Cartalax (C-tier) vs bpc-157 (A-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.
Cartalax — tier C
an identity-gated Ala-Glu-Asp tripeptide with cell and animal work plus one poorly reported, 29-person saline-controlled human example in an assignee patent, but no independent peer-reviewed replication or measured pharmacokinetic curve.
the exact AED tripeptide has a real chemical identity, preclinical signals, and one sparse assignee-patent human signal, but the consequential claims remain behind weak reporting, absent independent replication, and a product-identity gate.
29 people in patent Example 5 · half-life unknown; no measured concentration-time half-life · healing
bpc-157 — tier A
the contested repair peptide. strong animal data, thin human trials, huge community gravity.
the contested repair peptide. 200+ rat studies with consistent tissue-repair signals. zero published controlled human RCTs in tendon or injury recovery.
200+ rodent · 0 RCTs · half-life short (minutes IV) · healing
at a glance
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
